Literature DB >> 30470529

Systematic review analysis of robotic and transanal approaches in TME surgery- A systematic review of the current literature in regard to challenges in rectal cancer surgery.

Julia K Grass1, Daniel R Perez2, Jakob R Izbicki1, Matthias Reeh1.   

Abstract

Several patients' and pathological characteristics in rectal surgery can significantly complicate surgical loco regional tumor clearance. The main factors are obesity, short tumor distance from anal verge, bulky tumors, and narrow pelvis, which have been shown to be associated to poor surgical results in open and laparoscopic approaches. Minimally invasive surgery has the potential to reduce perioperative morbidity with equivalent short- and long-term oncological outcomes compared to conventional open approach. Achilles' heel of laparoscopic approaches is conversion to open surgery. High risk for conversion is evident for patients with bulky and low tumors as well as male gender and narrow pelvis. Hence, patient's characteristics represent challenges in rectal cancer surgery especially in minimally invasive approaches. The available surgical techniques increased remarkably with recently developed and implemented improvements of minimally invasive rectal cancer surgery. The controversial discussions about sense and purpose of these novel approaches are still ongoing in the literature. Herein, we evaluate, if latest technical advances like transanal approach or robotic assisted surgery have the potential to overcome known challenges and pitfalls in rectal cancer surgery in demanding surgical cases and highlight the role of current minimally invasive approaches in rectal cancer surgery.
Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Laparoscopy; Rectal cancer; Robotic surgery; Transanal

Mesh:

Year:  2018        PMID: 30470529     DOI: 10.1016/j.ejso.2018.11.010

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

1.  Feasibility of robot-assisted surgery in elderly patients with rectal cancer.

Authors:  Wei-Chih Su; Ching-Wen Huang; Cheng-Jen Ma; Po-Jung Chen; Hsiang-Lin Tsai; Tsung-Kun Chang; Yen-Cheng Chen; Ching-Chun Li; Yung-Sung Yeh; Jaw-Yuan Wang
Journal:  J Minim Access Surg       Date:  2021 Apr-Jun       Impact factor: 1.407

2.  Transanal versus Laparoscopic Total Mesorectal Excision in Male Patients with Low Tumor Location after Neoadjuvant Therapy: A Propensity Score-Matched Cohort Study.

Authors:  Ze Li; Jingkun Xiao; Yujie Hou; Xingwei Zhang; Haiqing Jie; Huashan Liu; Lei Ruan; Ziwei Zeng; Liang Kang
Journal:  Gastroenterol Res Pract       Date:  2022-02-27       Impact factor: 2.260

3.  Local recurrence of robot-assisted total mesorectal excision: a multicentre cohort study evaluating the initial cases.

Authors:  T A Burghgraef; R M P H Crolla; M Fahim; G P van der Schelling; A B Smits; L P S Stassen; J Melenhorst; P M Verheijen; E C J Consten
Journal:  Int J Colorectal Dis       Date:  2022-06-16       Impact factor: 2.796

4.  Cost analysis and cost-effectiveness of open versus laparoscopic versus robot-assisted versus transanal total mesorectal excision in patients with rectal cancer: a protocol for a systematic review.

Authors:  Ritchie T J Geitenbeek; Thijs A Burghgraef; Mark Broekman; Bram P A Schop; Tom G F Lieverse; Roel Hompes; Klaas Havenga; Maarten Postma; Esther C J Consten
Journal:  BMJ Open       Date:  2022-08-18       Impact factor: 3.006

5.  Prospective multicentre observational cohort to assess quality of life, functional outcomes and cost-effectiveness following minimally invasive surgical techniques for rectal cancer in 'dedicated centres' in the Netherlands (VANTAGE trial): a protocol.

Authors:  Ritch Geitenbeek; Thijs Burghgraef; Roel Hompes; David Zimmerman; Marcel Dijkgraaf; Maarten Postma; Adelita Ranchor; Paul Verheijen; Esther Consten
Journal:  BMJ Open       Date:  2022-08-19       Impact factor: 3.006

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.